As a state-owned company that is 129 years old, Bio Farma has gone through various dynamics and developments of the times. Gait in the vaccine industry is not spared from the steps of strategy and innovation. Not only successfully tested the business in the country, Bio Farma also has a name that counts in foreign countries.
Committed to follow the development of the pharmaceutical world, the company has launched a pentavalent vaccine product innovation with the trademark pentaBio Five in One. The contents consist of 5 antigens, namely DTP - HB - HIB (diphtheria, tetanus, pertussis, hepatitis B and Haemophilus influenzae type B. After going through a variety of rigorous tests, finally this innovative product is patented in liquid form. Even its existence has been recognized by WHO.
There is a value of concern that Bio Farma also wants to transmit to the community. We will always be committed to produce products that are environmentally friendly, control pollution, make continuous improvements, and save energy and natural resources.
We are very concerned about the safety factor for consumers, every Bio Farma product that is equipped with vaccine vial monitor (VVM) technology. This sign plays a role in measuring the quality of the vaccine. So that if exposed to undue temperature, the color indication on the vaccine packaging will change color.
We also divide the product distribution channel into two sectors, namely the government and the private sector. For the government sector, the Bio Farma vaccine is sent directly from the factory to the provincial health office to be distributed again to the level of government hospitals, health center and integrated service post in each area.
"Not only successfully tested domestic businesses, Bio Farma also has a name that is taken into account in foreign countries."
We also play a role and innovation in the international sphere, in addition to synergy with national research institutions, Bio Farma also relies on cooperation with various foreign research institutions in meeting the needs of developing countries. Bio Farma also cooperating with institutions such as the Organization of the Islamic Conference (OIC) and the Developing Countries Vaccine Manufacturer Network (DCVMN / vaccine producer organizations in developing countries).
The marketing of the vaccine also includes a pentavalent vaccine that has been launched domestically since 2013. In 2014 the vaccine was audited by WHO and received recognition in accordance with international standards. And since last year it has been exported to Egypt and other Arab countries.
Indonesia's share will also be even greater, so it is not limited to exporting finished products to 57 OIC member countries, but also sending semi-finished vaccines to the nine DCVMN vaccine producing countries. Furthermore, Bio Farma will conduct biotechnology transfers so that these countries are independent to provide vaccines to meet basic immunization programs.
At present, we also focus on research and development of quality and halal-certified products, we are trying to find solutions together with countries of Islamic cooperation organizations (OIC). This effort focuses on the search for halal criteria for medication.
Security Factors Become Important Attention of Bio Farma
Safety factors are also a concern for Bio Farma. This can be observed from every Bio Farma product equipped with Vaccine Vial Monitor (VVM) technology. This sign plays a role in measuring the quality of the vaccine. Because, if exposed to undue temperatures, the vaccine will change color.
For domestic vaccine needs, Bio Farma divides its product distribution channels into two sectors, namely the government and the private sector. For the government sector, Bio Farma vaccine was sent directly from the factory to the provincial health office to be distributed again to the level of government hospitals, health center and integrated service post in each area.
What about action in the international sphere? In addition to synergies with national research institutions, Bio Farma also relies on cooperation with various foreign research institutions in meeting the needs of developing countries. Bio Farma also cooperates with institutions such as the Organization of the Islamic Conference (OIC) and the Developing Countries Vaccine Manufacturer Network (DCVMN / vaccine producer organizations in developing countries).
CONTRIBUTED TO THE HEALTH OF NATION THROUGH THE YEARS
ACCESS TO HEALTH AND ACCELERATION OF PHARMACEUTICAL INDUSTRY DEVELOPMENT.
According to the instruction of the president of the Republic of Indonesia number 6 of 2016 concerning the acceleration of the development of the pharmaceutical industry and medical devices, Bio Farma always supports the acceleration of the development of the pharmaceutical and medical devices industry, by ensuring the availability of pharmaceutical preparations and medical devices as an effort to improve health services in the context of National Health Insurance.
Bio Farma is committed to improve the competitiveness of the pharmaceutical industry and medical devices in the country and exports. Currently with a number of 13 products that have received recognition - Pre Qualification from the World Health Organization (WHO) More than 130 countries have used Bio Farma products, we have become The largest vaccine manufacturer in Southeast Asia with a production capacity of more than 3.2 billion doses per year. However, we always prioritize the need for domestic vaccines.
Bio Farma encourages the mastery of technology and innovation in the field of pharmaceuticals and medical devices and accelerates the independence and development of raw material production to meet domestic and export needs and restore and increase industrial activities / industrial capacity utilization.
We are committed to the development of the pharmaceutical industry and medical devices especially the development towards Biopharmacutical, vaccines, natural, and Active Pharmaceutical Ingredients (API) chemicals. Through our national vaccine research and life-science research forums, we encourage and develop research and development of pharmaceutical preparations and medical devices in the context of the independence of the pharmaceutical industry and medical devices.
Bio Farma continues to make proud achievements. PROPER Gold Award was won for three consecutive years (2014, 2015, 2016) from the Ministry of Environment and Forestry. Moreover, Bio Farma is the only pharmaceutical company that won the Gold PROPER award. At the 2012 Indonesia Green Company event held by SWA, Bio Farma was selected as one of the best companies.
BIO FARMA WINS TOP IT AWARD FOR DIGITAL AND TRACE SYSTEM
Bio Farma won the TO P IT award for its Digital Track and Trace System in 2018. Company President Director Rahman Rustan won the Top Leader in IT Leadership 2018 from the IT Work Magazine. Presenting both awards was the Organizing Chairman and Editor in Chief of IT Work, M. Lutfi Handayani. The awards were conferred to recognize digital innovations to prevent counterfeit vaccines.
Track & Trace is a digital innovation developed by Bio Farma. The innovation has undergone trials for recentlylaunched products from a number of distribution channels all the way to consumers. In the future, the system will gradually encompass all of the Company’s products.
As Indonesia enters the Industrial Revolution 4.0, Bio Farma’s Long-term Company Plan 2018-2022 looks at digital transformation by leveraging business intelligence, big data, and bioinformatics. The technologies are expected to assist the management to shift business decisions from enabler to driver.
Bio Farma’s digital transformation focuses on at least three main areas: customer experience, operational processes, and business model. The goals of these focuses are improving customer satisfaction, operating efficiency, faster decision making, and rapid adaptation to change.